Document is current
Any future updates will be listed below
-
Authors
Wickman, Elizabeth https://orcid.org/0000-0001-7086-9084
Lange, Shannon
Wagner, Jessica
Ibanez, Jorge
Tian, Liqing
Lu, Meifen
Sheppard, Heather
Chiang, Jason
Koo, Selene C
Vogel, Peter
Langfitt, Deanna
Perry, S Scott
Shanmugam, Raghuvaran
Bell, Matthew
Shaw, Timothy I
Krenciute, Giedre https://orcid.org/0000-0003-4335-0644
Zhang, Jinghui
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04684563 at ClinicalTrials.govnct01050296 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.
https://doi.org/10.1200/jco.2024.42.16_suppl.7004
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors
https://doi.org/10.1136/jitc-2024-009743
CARs are sharpening their weapons
https://doi.org/10.1136/jitc-2023-008275
557 Evaluation of huCART19-IL18 manufactured using Synecta™ CDNP technology to improve CAR-T yield and consistency in cohort D of an ongoing phase I study (NCT04684563)
https://doi.org/10.1136/jitc-2025-sitc2025.0557
Documents that mention this clinical trial
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors
https://doi.org/10.1136/jitc-2024-009743
-
Funding
Funding for this research was provided by:
Alex Lemonade Stand Foundation (N/A)
American Lebanese Syrian Associated Charities (N/A)
Cure4Cam (N/A)
National Cancer Institute (1F31CA257757)
National Cancer Institute (F31CA250401-01A1)
National Cancer Institute (P30CA021765)
National Cancer Institute (R01NS121249)
National Cancer Institute (R01NS122859)
Alliance for Cancer Gene Therapy (N/A)
- License Information
